Compare Microsoft (MSFT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

MicrosoftTrade

Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Microsoft vs Regeneron Pharmaceuticals Inc — how do they compare? Microsoft trades at $396.09 (market cap $2.99T), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Microsoft is far larger — about 42.4× Regeneron Pharmaceuticals Inc's market cap, and Microsoft pays the higher dividend (0.9%). Which is the better fit depends on your goals.

	MSFT	REGN
Market Cap	$2.99T	$70.47B
Volume	36,654,621	—
Sector	Technology	Health
52-Week High	$542.07	$812.27
52-Week Low	$352.83	$545.46
Enterprise Value	$2.97T	$64.42B
Dividend Yield	0.9%	0.56%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Microsoft

Microsoft trades at $397.75, up 1.0% with strong technical momentum as price approaches pivot point resistance at $398. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.27 versus $4.06, continuing a trend of earnings outperformance. Revenue growth accelerated to $281.72B in 2025 with net income margins expanding to 36.14%. Recent news highlights Microsoft's AI leadership through Azure and Copilot initiatives, though concerns about capital expenditures persist.

Microsoft presents a compelling investment case with 80% analyst buy ratings and a $546.70 consensus price target representing 37% upside. The company's AI positioning and cloud dominance support long-term growth, but risks include competitive pressures, high valuation multiples (P/E 23.96), and market volatility. Strong cash flow generation ($136.16B operating cash flow) and consistent dividend payments provide shareholder stability amid growth investments.

Regeneron Pharmaceuticals Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MSFT

Roundhill Magnificent Seven ETF offers equal exposure to top 7 mega-cap tech stocks but with higher risk and cost.24/7 Wall Street · 7 hours agoNeutral Microsoft shifts to AI-driven revenue model amid record $190B capex and strong demand.Seeking Alpha · 8 hours agoBullish OpenAI and Anthropic boost lobbying to $3.17M in Q2 ahead of IPOs and midtermsCNBC · 10 hours agoNeutral View details →

REGN

Telix reports Q2 revenue of $247M, strong growth, and advances in cancer therapy trials.GlobeNewsWire · 1 day agoBullish Lawsuit alleges Regeneron misled investors on drug trial results, causing stock to drop sharply.GlobeNewsWire · 4 days agoBearish Class action lawsuit filed against Regeneron over misleading trial results and stock price drop.GlobeNewsWire · 4 days agoBearish View details →

About Microsoft

Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases